natgillin/translations-raw huggingface dataset:
The composition of claim 28, wherein said additional anti-hepatitis C virus agent is selected from the group consisting of a-interferon, β-interferon, ribavarin, and adamantine. 
Pripravak u skladu s patentnim zahtjevom 28, naznačen time, da je rečeno dodatno sredstvo protiv virusa hepatitisa C odabrano iz skupine koja se sastoji od a-interferona, β-interferona, ribavarina i adamantina.
The pharmaceutical composition of claim 24, further comprising an agent selected from interferon, ribavirin, amantadine, another HCV protease inhibitor, an HCV polymerase inhibitor, an HCV helicase inhibitor, or an internal ribosome entry site inhibitor. The pharmaceutical composition of claim 24, further comprising pegylated interferon. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 24, naznačen time, da nadalje sadrži sredstvo odabrano od interferona, ribavirina, amantadina, drugog inhibitora HCV proteaze, inhibitora HCV polimeraze, inhibitora HCV helikaze ili inhibitora internog mjesta ulaska ribozoma.
is a charge neutral masking agent containing a targeting moiety, 
je maskirajuće sredstvo neutralnog naboja koje sadrži derivat galaktoze,
N is an RNA interference polynucleotide, A is a galactose trimer or a hydrophobic group having at least 20 carbon atoms, y is an integer greater than or equal to 1 and z is an integer greater than or equal to 0 wherein the value of y and z together is greater than 50% of the number of amines of the polyamine P; 
je maskirajuće sredstvo neutralnog naboja koje sadrži polietilen glikol, N je RNA interferencijski polinukleotid, A je trimer galaktoze ili hidrofobna skupina koja ima barem 20 ugljikovih atoma, y je cijeli broj veći ili jednak 1 i z je cijeli broj veći ili jednak 0 pri čemu vrijednost y i z zajedno je veća od 50% broja amina u poliaminu P;
N and A are not, directly or indirectly, covalently linked to P, L2, M1 or M2. 
N i A nisu, izravno ili neizravno, kovalentno vezani na P, L2, M1 ili M2.
Delivery system according to claim 1 or claim 2, wherein L2 is a maleamate linkage. 
Sustav za isporuku prema zahtjevu 1 ili zahtjevu 2, naznačen time da L2 je maleamatna veza.
Delivery system according to claim 3, wherein L2 is a disubstituted maleamate linkage; 
Sustav za isporuku prema zahtjevu 3, naznačen time da L2 je dvostruko supstituirana maleamatna veza;
Delivery system of claim 8 wherein P is a random copolymer of poly(vinyl ether) and poly(acrylate). 
Sustav za isporuku prema zahtjevu 8 naznačen time da P je slučajan kopolimer poli(vinil etera) i poli(akrilata).
Delivery system of claim 1, wherein the ratio of targeting moiety to steric stabilizer linked to P is 1 to 0.5-2. 
Sustav za isporuku prema zahtjevu 1, naznačen time da omjer derivata galaktoze prema polietilen glikolu PEG vezanom na P je 1 do 0.5-2.
Delivery system of claim 1 wherein the galactose trimer consists of an N-acetylgalactosamine trimer. 
Sustav za isporuku prema zahtjevu 1 naznačen time da derivat galaktoze sadrži N-acetilgalaktozamin.
linking the RNA interference polynucleotide to a galactose trimer or a hydrophobic group having at least 20 carbon atoms; 
vezanje RNA interferencijskog polinukleotida na trimer galaktoze ili na hidrofobnu skupinu koja ima barem 20 ugljikovih atoma;
providing the RNA interference polynucleotide and the reversibly inhibited membrane active polyamine in solution suitable for administration in vivo. wherein said RNA interference nucleotide linked to said galactose trimer or a hydrophobic group having at least 20 carbon atoms, is not, directly or indirectly, covalently linked to said reversibly inhibited membrane active polyamine. 
osiguravanje RNA interferencijskog polinukleotida i reverzno inhibiranog membranski aktivnog poliamina u otopini pogodnoj za davanje in vivo, pri čemu navedeni RNA interferencijski nukleotid koji je vezan na navedeni trimer galaktoze ili na hidrofobnu skupinu koja ima barem 20 ugljikovih atoma, nije, izravno ili neizravno, kovalentno vezan na navedeni reverzno inhibirani membranski aktivni poliamin.
Method to store or increase the energy content of a reaction mixture, said reaction being enabled by the heat input from a heat source distinct from said reaction mixture, characterized in that the energy content of the reaction mixture is stored or increased by means of an endothermic condensation reaction, said reaction mixture comprising an inorganic oxoacid compound and/or its salt and water. 
Postupak za skladištenje ili povećanje sadržaja energije reakcijske smjese, pri čemu je spomenuta reakcija omogućena dovođenjem energije iz izvora topline koji nije identičan sa spomenutom reakcijskom smjesom, naznačen time što se sadržaj energije reakcijske smjese skladišti ili povećava endotermnom reakcijom kondenzacije, pri čemu spomenuta reakcijska smjesa sadrži neorganski oksokiselinski spoj i/ili njegovu sol i vodu.
Method according to claim 1, wherein the heat source distinct from said reaction mixture is either rest heat from industrial processes, or heat derived from natural resources such as solar or wind energy. 
Postupak prema zahtjevu 1, pri čemu je izvor topline koji nije identičan sa spomenutom reakcijskom smjesom ostatak topline iz industrijskih procesa, ili topline koja potiče iz prirodnih izvora, kao što je solarna energija ili energija vjetra.
Method according to claim 1 or 2, wherein water and/or the inorganic oxoacid compound and/or its salt is removed from the reaction mixture. 
Postupak prema zahtjevu 1 ili 2, pri čemu se voda i/ili neorganski oksokiselinski spoj i/ili njegova sol odstranjuju iz reakcijske smjese.
increased energy content of the reaction mixture in a subsequent process step through the exothermic hydrolysation of the reaction products of said reaction mixture. 
povećanog sadržaja energije reakcijske smjese u sljedećem procesnom koraku egzotermnom hidrolizacijom reakcijskih proizvoda spomenute reakcijske smjese.
Method according to any of the claims 1 through 3, wherein the inorganic oxoacid compound and/or its salt is an oxoacid of either nitrogen, sulfur or phosphorus, or its corresponding salt. 
Postupak prema bilo kom od zahtjeva 1 do 3, pri čemu je anorganski oksokiselinski spoj i/ili njegova sol oksokiselina dušika, sumpora ili fosfora, ili njegova odgovarajuća sol.
X represents sulfur, nitrogen or phosphorus; 
X predstavlja sumpor, dušik ili fosfor;
Method according to claim 5, wherein the polyphosphoric acids or their salts are; 
Postupak prema zahtjevu 5, pri čemu su polifosforne kiseline ili njihove soli:
combinations thereof. Method according to claim 6, 7 or 8, wherein the metal cation is a monovalent metal cation, more in particular K or Na. 
Postupak prema zahtjevu 6, 7 ili 8, pri čemu je kation metala monovalentni kation metala, još poželjnije K ili Na.
Method according to claim 7 wherein the salts of phosphoric acids are selected from the group containing Phosphoenolpyruvate, Glycerate 1,3 bi phosphate,Formyl phosphate, Acetyl phosphate,Propionyl phosphate,Butyryl phosphate or other carboxyl phosphates, Phospho-creatine, Phospho-arginine, Glucose phosphates (1 or 6-phosphate), fructose phosphates, Glycerol-3-phosphate, Nicotine amide adenine dinucleotide phosphate (NADP), dihydroxyacetonephosphate,glyceraldehydephosphates, xylulosephosphate,ribosephosphates,sedoheptulosepho sphate,Erythrosephosphate, ribuloseophosphate phospho-serine, Aspartylphosphate and adenosinephosphate. 
Postupak prema zahtjevu 7, pri čemu su soli fosfornih kiselina izabrane iz grupe koja sadrži fosfoenolpiruvat, glicerat 1,3 bifosfat, formil fosfat, acetil fosfat, propionil fosfat, butiril fosfat ili druge karboksil fosfate, fosfo-kreatin, fosfo-arginin, glukoza fosfate (1 ili 6-fosfat), fruktoza fosfate, glicerol-3-fosfat, nikotin amid adenin dinukleotid fosfat (NADP), dihidroksiacetonfosfat, gliceraldehidfosfate, ksilulozafosfat, ribozafosfate, sedoheptuloza fosfat, eritrozafosfat, ribulozaofosfat fosfo-serin, aspartilfosfat i adenozinfosfat.
Method according to any of claims 1 to 6, wherein the endothermic condensation reaction is represented by the following formula: 
Postupak prema bilo kom od zahtjeva 1 do 6, pri čemu je endotermna reakcija kondenzacije predstavljena sljedećom formulom:
The system according to claim 14, further characterized in that it comprises a release means for releasing the energy captured and stored in a subsequent exothermic hydrolysis step. 
Sistem prema zahtjevu 14, koji je dalje naznačen time što sadrži sredstva za oslobađanje sakupljene i uskladištene energije u sljedećem koraku egzotermne hidrolize.
The compound 2-amino-3-methyl-hex-5-enoic acid or salts thereof. 
Spoj 2-amino-3-metil-heks-5-enoična kiselina ili njezine soli.
Method of producing 2-amino-3-methyl-hex-5-enoic acid, comprising a cross coupling of a vinyl Grignard agent with an alkyl halide. 
Postupak proizvodnje 2-amino-3-metil-heks-5-enoične kiseline, naznačen time da sadrži unakrsno spajanje vinil Grignardova reagensa s alkil halidom.
and its salts of addition with pharmaceutically acceptable organic and inorganic acids and bases; 
te njegove adicijske soli s farmaceutski prihvatljivim organskim i anorganskim kiselinama i lužinama;
H-indazole-3-carboxamide compounds according to claim 2, wherein Ra and Ra', equal or different each other, is a halogen atom, selected from chlorine or bromine; a hydroxy group; a C1-C6 alkyl group; a C1-C6 alkoxy group; or a carbocyclic or heterocyclic ring, saturated or unsaturated, having from 5 to 6 members, optionally substituted by one or more substituents, selected from the group consisting of halogen, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, -NR1R2 and -COOH; and R1 and R2 are independently a hydrogen atom, a C1-C4 alkyl group, a C2-C4 alkenyl group, a C2-C4 alkynyl group, and a phenyl group. 
Spojevi 1H-indazol-3-karboksamida prema zahtjevu 2, naznačeni time, da su svaki od Ra i Ra' međusobno isti ili različiti, sljedeći: atom halogena odabran od klora ili broma; hidroksi skupina; C1-C6 alkil-skupina; C1-C6 alkoksi-skupina; ili karbociklički ili heterociklički prsten, zasićen ili nezasićen, koji ima od 5 do 6 članova, opcijski supstituiran s jednim ili više supstituenata odabranih iz skupine koju čine halogen, hidroksi, C1-C6 alkil, C1-C6 alkoksi, -NR1R2 -COOH; i i R2 su neovisno vodikov atom, C1-C4 alkil-skupina, C2-C4 alkenil-skupina, -C4 alkinil-skupina i fenil-skupina.
H-indazole-3-carboxamide compounds according to claim 3, wherein Ra and Ra', equal or different each other, is a bromine atom, a hydroxy group; a C1-C3 alkoxy group; or an unsaturated carbocyclic or heterocyclic ring, having 6 members, optionally substituted by one or two substituents selected from the group consisting of halogen, hydroxy, C1-C3 alkyl, C1-C3 alkoxy, -NR1R2 and -COOH; and R1 and R2 are independently a hydrogen atom, a C1-C4 alkyl group, a C2-C4 alkenyl group, a C2-C4 alkynyl group, and a phenyl group. 
Spojevi 1H-indazol-3-karboksamida prema zahtjevu 3, naznačeni time, da su svaki od Ra i Ra' međusobno isti ili različiti, sljedeći: atom broma; hidroksi skupina; C1-C3 alkoksi-skupina; ili nezasićeni karbociklički ili heterociklički prsten koji ima 6 članova, opcijski supstituiran s jednim ili dva supstituenta odabrana iz skupine koju čine halogen, hidroksi, C1-C3 alkil, C1-C3 alkoksi, -NR1R2i -COOH; i i R2 su neovisno vodikov atom, C1-C4 alkil-skupina, C2-C4 alkenil-skupina, -C4 alkinil-skupina i fenil-skupina.
H-indazole-3-carboxamide compounds according to claim 6, wherein Y is a C1-C3 alkyl group. 
Spojevi 1H-indazol-3-karboksamida prema zahtjevu 6, naznačeni time, da Y je C4-C3 alkil-skupina.
H-indazole-3-carboxamide for the use according to claim 1, wherein said insulin-resistance disorders are selected from the group consisting of type-2 diabetes, syndrome X, obesity and polycystic ovary syndrome. 
H-indazol-3-karboksamid za uporabu prema zahtjevu 1, naznačen time, da su navedeni poremećaji zbog otpornosti na inzulin, odabrani iz skupine koju čine dijabetes tipa 2, sindrom X, pretilost i sindrom policističnih jajnika.
H-indazole-3-carboxamide for the use according to claim 1, wherein said neurodegenerative diseases are selected from the group consisting of Parkinson's disease, Alzheimer's disease, Huntington's disease, and spinal neurodegenerative disorders. 
H-indazol-3-karboksamid za uporabu prema zahtjevu 1, naznačen time, da su navedene neurodegenerativne bolesti odabrane iz skupine koju čine Parkinsonova bolest, Alzheimerova bolest, Hungtingtonova bolest i spinalni neurodegenerativni poremećaji.
H-indazole-3-carboxamide for the use according to claim 3, wherein said spinal neurodegenerative disorders are selected from the group consisting of amyotrophic lateral sclerosis, multiple sclerosis, spinal muscular atrophy and neurodegeneration due to spinal cord injury. 
H-indazol-3-karboksamid za uporabu prema zahtjevu 3, naznačen time, da su navedeni spinalni neurodegenerativni poremećaji odabrani iz skupine koju čine amiotrofna lateralna skleroza, multipla skleroza, spinalna muskularna atrofija i neurodegeneracija zbog ozljede kralježnične moždine.
H-indazole-3-carboxamide for the use according to claim 1, wherein said mood disorders are selected from the group consisting of bipolar disorders and depressive disorders. 
H-indazol-3-karboksamid za uporabu prema zahtjevu 1, naznačen time, da su navedeni poremećaji raspoloženja, odabrani iz skupine koju čine bipolarni poremećaji i depresivni poremećaji.
H-indazole-3-carboxamide for the use according to claim 5, wherein said bipolar disorders are selected from the group consisting of bipolar I, bipolar II, cyclothymia and bipolar disorder not otherwise specified (BD-NOS). 
H-indazol-3-karboksamid za uporabu prema zahtjevu 5, naznačen time, da su navedeni bipolarni poremećaji odabrani iz skupine koju čine bipolar I, bipolar II, ciklotimija i bipolarni poremećaj koji nije drugačije opisan (BD-NOS).
H-indazole-3-carboxamide for the use according to claim 1, wherein said substance abuse disorders are selected from the group of abuse disorders due to psychostimulants. 
H-indazol-3-karboksamid za uporabu prema zahtjevu 1, naznačen time, da su navedeni poremećaji zbog zlouporabe droga, odabrani iz skupine poremećaja zlostavljanja zbog psihostimulacijskih sredstava.
H-indazole-3-carboxamide for the use according to claim 12, wherein said schizophrenic disorders are selected from the group consisting of paranoid schizophrenia, disorganized schizophrenia, catatonic schizophrenia, simple schizophrenia, residual schizophrenia, and undifferentiated schizophrenia. 
H-indazoI-3-karboksamid za uporabu prema zahtjevu 12, naznačen time, da su navedeni shizofrenični poremećaji odabrani iz skupine koju čine paranoidna shizofrenija, dezorganizacijska shizofrenija, katatonička shizofrenija, jednostavna shizofrenija, rezidualna shizofrenija i nediferencirana shizofrenija.
1H-indazole-3-carboxamide for the use according to claim 1, wherein said cancerous disorders are selected from the group consisting of prostate, pancreatic, ovarian, and colon-rectal cancer and MLL-associated leukaemia. 
H-indazol-3-karboksamid za uporabu prema zahtjevu 1, naznačen time, da su navedeni kancerogeni poremećaji odabrani iz skupine koju čine rak prostate, rak gušterače, rak jajnika i kolorektalni rak, te leukemija povezana s MLL.
A pharmaceutical composition comprising an effective amount of at least one compound of formula (I) as defined in anyone of claims 1-11 above, a salt thereof with a pharmaceutically acceptable organic or inorganic acid or base, or an ester prodrug thereof, and at least one inert pharmaceutically acceptable excipient. 
Farmaceutski sastav, naznačen time, da on obuhvaća učinkovitu količinu najmanje jednog spoja formule (I) prema bilo kojem od zahtjeva 1 do 11, njegovu sol s farmaceutski prihvatljivom organskom ili anorganskom kiselinom ili lužinom, ili njegovu estersku prosupstancu, te najmanje jedno inertno farmaceutski prihvatljivo pomoćno sredstvo.
The method according to claim 1, wherein the horseshoe is manufactured of a material selected from the group consisting of steel, aluminum, titanium, copper, and an admixture thereof. 
Potkovica prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time da je proizvedena od materijala izabranog iz grupe koja obuhvaća: metal, čelik, aluminij, titan, bakar, plastiku ili mješavinu ovih materijala.
connecting three-dimensional object (5) having processed inner side onto inward facing surface of an outer shell (1.1) which is formed by carving from the said transparent stone's (1) inner side. 
povezivanje trodimenzionalnog objekta (5) na unutarnjoj površini vanjske ljuske (1.1) koja se formira rezbarenjem unutarnje površine navedene vanjske ljuske (1.1).
A method to form a three-dimensional image inside transparent stone (1) comprising the following process steps: 
Postupak formiranja trodimenzionalne slike unutar transparentnog kamena (1) koji obuhvaća sljedeće korake procesa:
provided that: when Q2 is a phenyl ring substituted on at least one ortho position with a substituent selected from -U-V-T wherein U is a direct bond, V is C(=O) and T is NR23aR23b or OR24, then X is other than NR4; 
uz uvjet da: kada je Q2 jednak fenil prsten supstituiran na najmanje jednim orto položajem sa supstituentom izabranim od -U-V-T, gdje U je direktna veza, V je C(=O) i T je NR23aR23b ili OR24, tada se X razlikuje od NR4;
and provided that the compound of Formula 1 is other than: 
i uz uvjet da se spoj formule 1 razlikuje od:
is H, C1-C6 alkyl, C1-C6 haloalkyl or C4-C8 alkylcycloalkyl; or R6 and R7 are taken together with the nitrogen atom to which they are connected to form a four- to seven-membered nonaromatic heterocyclic ring containing ring members, in addition to the connecting nitrogen atom, selected from carbon atoms and up to one ring member selected from O and NR13; 
je H, C1-C6 alkil, C1-C6 haloalkil ili C4-C8 alkilcikloalkil; ili i R7 povezani sa atomom dušika za koji su vezani tako da formiraju četvoro- do sedmo-člani nearomatični heterociklični prsten koji sadrži članove prstena, pored vežućeg atoma dušika, izabrane od atoma ugljika i do jedan član prstena izabran od O i NR13;
A fungicidal composition comprising: (a) a compound of any of Claims 1 to 13; and (b) at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents. 
Fungicidna kompozicija koja sadrži: (a) spoj prema bilo kojem od patentnih zahtjeva 1 do 13; i (b) najmanje jednu dodatnu komponentu izabranu iz grupe koja se sastoji od surfaktanata, čvrstih razblaživača i tekućih razblaživača.
The inhaler according to claim 4 wherein the ratio of the sum of the cross-sectional areas of the apertures in the second circumferential flange (208; 308; 508; 705) to the cross-sectional area of the first conduit (101; 202; 302; 507; 602; 703) is such that when a pressure breath induced low pressure is applied to the distal end of the airflow adaptor (101; 202; 302; 507; 602; 703) at least 20%, of the resulting airflow is through the apertures. 
Inhalator prema zahtjevu 4 gdje je omjer zbroja poprečnih presjeka otvora u drugoj obodnoj prirubnici (208; 308; 508; 705) prema poprečnom presjeku prve cijevi (101; 202; 302; 507; 602; 703) takav da kada se disanjem nastali niski tlak primijeni na distalni kraj adaptora protoka zraka (101; 202; 302; 507; 602; 703) barem 20% nastalog protoka zraka bude kroz otvore.
A method for modifying airflow through the outlet port of a deagglomerator of a breath-actuated dry powder inhaler comprising the steps of: 
Postupak za podešavanje protoka zraka kroz izlaz deaglomeratora inhalatora suhog praha koji se aktivira disanjem, a koji obuhvaća korake:
The method of claim 1, wherein the non-cancerous biological sample comprises white blood cells. 
Postupak prema zahtjevu 1, gdje su biološki uzorak krvne stanice dobivene od bolesnika.
Nucleic acid molecule encoding a peptide according to claim 3 or a molecule according to 4 or 5. 
Molekula nukleinske kiseline, naznačena time, da kodira peptid prema zahtjevu 4 ili fuzijski protein prema zahtjevu 5 ili 6.
Vaccine formulation according to claim 1 or 2, characterised in that the formulation comprises further at least one pharmaceutical acceptable adjuvant, excipient and/or carrier. 
Formulacija cjepiva prema zahtjevu 1 ili 2, naznačena time, da formulacija obuhvaća dodatno najmanje jedan farmaceutski prikladan adjuvant, pomoćno sredstvo i/ili nosač.
Vaccine formulation comprising a peptide consisting of SEQ ID No. 52. 
Formulacija cjepiva, naznačena time, da obuhvaća peptid koji se sastoji od SEQ ID NO:52.
Nucleic acid molecule encoding a peptide according to claim 4 or a fusion protein according to claim 5 or 6. 
Molekula nukleinske kiseline, naznačena time, da kodira peptid prema zahtjevu 4 ili fuzijski protein prema zahtjevu 5 ili 6.
Vaccine formulation comprising at least one fusion protein according to claim 5 or 6, preferably comprising further at least one pharmaceutical acceptable adjuvant, excipient and/or carrier. 
Formulacija cjepiva, naznačena time, da sadrži najmanje jedan fuzijski protein prema zahtjevu 5 ili 6, te poželjno nadalje sadrži najmanje jedan farmaceutski prikladan adjuvant, pomoćno sredstvo i/ili nosač.
a spherical formed body (10), 
sferno formirano tijelo (10),
A pharmaceutical composition according to any of the claims 1 to 21 and 29 for treatment of hyper-proliferative disorders in a mammal, including a human, either as sole agent or in combination with other therapies. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 15 naznačen time da je za uporabu za liječenje hiper-proliferativnih poremećaja kod sisavca, uključujući čovjeka, bilo kao jedino sredstvo ili u kombinaciji s drugim terapijama.
A pharmaceutical composition according to any of the claims 1 to 21 and 29 for treatment of cancer ina mammal, including a human, either as sole agent or in combination with other therapies. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 15 naznačen time da je za uporabu za liječenje raka kod sisavca, uključujući čovjeka, bilo kao jedino sredstvo ili u kombinaciji s drugim terapijama.
A pharmaceutical composition according to any of the claims 1 to 21 and 29 for treatment of cancer in a human patient, in combination with a cytotoxic therapy. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 15 naznačen time da je za uporabu za liječenje raka kod pacijenta koji je čovjek, u kombinaciji s citotoksičnom terapijom.
A composition according to claim 1 wherein the matrix comprises a pharmaceutically acceptable polymer selected from the group consisting of polyvinylpyrrolidone, vinylpyrrolidone/ vinylacetate copolymer, polyalkylene glycol, polyethylene glycol, hydroxyalkyl cellulose, hydroxypropyl cellulose, hydroxyalkyl methyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, ethyl cellulose, polymethacrylates, polyvinyl alcohol, polyvinyl acetate, vinyl alcohol/vinyl acetate copolymer, polyglycolized glycerides, xanthan gum, carrageenan, chitosan, chitin, polydextrin, dextrin, starch and proteins. 
Pripravak prema zahtjevu 1 naznačen time da matrica sadrži farmaceutski prihvatljiv polimer odabran iz skupine koju čine polivinilpirolidon, kopolimer vinilpirolidon/vinilacetat, polialkilen glikol, polietilen glikol, hidroksialkil celuloza, hidroksipropil celuloza, hidroksialkil metil celuloza, hidroksipropil metil celuloza, karboksimetil celuloza, natrijeva karboksimetil celuloza, etil celuloza, polimetakrilati, polivinil alkohol, polivinil acetat, kopolimer vinil alkohol/vinil acetat, poliglikolizirani gliceridi, ksantan guma, karagenan, kitosan, kitin, polidekstrin, dekstrin, škrob i proteini.